Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
Abstract Over the last 50 years, there has been a steady improvement in the treatment outcome of acute myeloid leukemia (AML). However, median survival in the elderly is still poor due to intolerance to intensive chemotherapy and higher numbers of patients with adverse cytogenetics. Fadraciclib (CYC...
| المؤلفون الرئيسيون: | , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Nature Publishing Group
2021-06-01
|
| سلاسل: | Cell Death Discovery |
| الوصول للمادة أونلاين: | https://doi.org/10.1038/s41420-021-00496-y |